News | February 25, 2025
Teva and Sanofi present new outcome from Phase 2b study of duvakitug
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Cancer cases in India estimated to reach 1.57 million in 2025
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
Subscribe To Our Newsletter & Stay Updated
